Intravascular Coronary Imaging and Physiology

Intravascular Coronary Imaging and Physiology is a one-and-a-half-day program providing both detailed and broad examinations of basic and advanced clinical techniques, a review of relevant trial data, and discussion on recent developments in device concepts. Multiple didactic sessions with opportunities for Q&A will be intertwined with several live cases from St. Francis Hospital.

February 4, 2016 — Stereotaxis and Philips have signed an addendum pursuant to their existing Development and Cooperation Agreement to facilitate development of a new interface between each company’s most advanced systems for electrophysiology (EP) and interventional cardiology procedures.

New research from scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) published in the journal Circulation, may lead to a new approach to help treat heart failure early in the disease.

Biotronik announced CE approval for its new Ilivia implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy devices (CRT-Ds), improving magnetic resonance imaging (MRI) access for cardiac device patients. Ilivia devices come with the company’s ProMRI technology, as well as MRI AutoDetect.

Abbott and Alere Inc. announced a definitive agreement for Abbott to acquire Alere. Under the terms of the agreement, Abbott will pay $56 per common share at a total expected equity value of $5.8 billion.

Medtronic announced Feb. 3 that the U.S. Food and Drug Administration (FDA) revised the CoreValve’s instructions for use (IFU) labeling to include patients with end-stage renal disease and low flow, low gradient aortic stenosis. Previously, physicians were cautioned against treating these patients with transcatheter aortic valve replacement (TAVR) because of their severe comorbidities.

Stanford Health Care recently released a new app that allows patients using Android smartphones to easily access their own medical information anywhere in the world.

Medtronic plc announced the recent CE Mark and commercial launch for an expanded size matrix of the Resolute Onyx DES, a next-generation drug-eluting stent now available in 4.5 and 5 mm diameter sizes. The CE Mark also approved several new product indications including treatment of left main vessels and small vessels.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now